Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery-Reference-Cited by-同舟云学术

Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery

Published:2020-08-19 Issue:5 Volume:15 Page:321-339
ISSN:1744-6651
Container-title:Expert Review of Endocrinology & Metabolism
language:en
Short-container-title:Expert Review of Endocrinology & Metabolism

Author:

Capatina Cristina¹,Hinojosa-Amaya José Miguel²³,Poiana Catalina¹,Fleseriu Maria²^ORCID

Affiliation:

1. Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania

2. Departments of Medicine (Endocrinology) and Neurological Surgery, and Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA

3. Endocrinology Division, Department of Medicine, Hospital Universitario Dr. José E. González, Universidad Autónoma De Nuevo León, Monterrey, Nuevo León, Mexico

Publisher

Informa UK Limited

Subject

Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/17446651.2020.1802243

Reference219 articles.

1. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Diagnosis of Recurrence in Cushing Disease

2. Late Recurrences of Cushing’s Disease after Initial Successful Transsphenoidal Surgery

3. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome

4. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

5. EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulation Patterns of Functional Corticotroph Tumors Correlate with Tumor Size, Proliferative Activity, T2 Intensity-to-White Matter Ratio, and Postsurgical Early Biochemical Remission;Endocrine Pathology;2024-07-24

2. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease;Frontiers in Endocrinology;2023-10-09

3. Risk of impulse control disorders in patients with Cushing’s disease: do not blame cabergoline but do not give up caution;Pituitary;2023-07-20

4. Ketoconazole as second-line treatment for Cushing’s disease after transsphenoidal surgery: systematic review and meta-analysis;Frontiers in Endocrinology;2023-05-08

5. Refractory corticotroph adenomas;Pituitary;2023-03-14